Healthcare (603313) 国投证券·2025-05-19 05:57Investment Rating - The investment rating for the company is "Buy-A" with a target price of 8.68 CNY, based on a 19x PE for 2025 [4][9][13]. Core Insights - The company achieved a revenue of 8.449 billion CNY in 2024, representing a year-on-year growth of 5.94%. The net profit attributable to shareholders was -151 million CNY, a decline of 242.04% year-on-year [2][9]. - In Q1 2025, the company reported a revenue of 2.043 billion CNY, a year-on-year increase of 12.31%, and a net profit of 59 million CNY, up 196.22% year-on-year [1][3]. - The company is focusing on global capacity and brand internationalization, with significant performance in the European market, which has seen double-digit growth for two consecutive years [2][9]. Revenue and Profitability - The company's mattress business generated 4.415 billion CNY in 2024, growing by 10.95% year-on-year, while the bedding business saw a decline of 4.08% to 596 million CNY [2][10]. - The gross margin for 2024 was 36.85%, down 1.50 percentage points year-on-year, but improved to 39.37% in Q1 2025, an increase of 0.84 percentage points [3][7]. - The net profit margin for 2024 was -2.12%, with a significant recovery to 2.59% in Q1 2025 [7][9]. Market Position and Strategy - The company is positioned as a leading domestic memory foam mattress brand, benefiting from its global production layout and brand internationalization strategy [9][11]. - The impact of U.S. tariffs has been limited, and the company is leveraging its local production advantages in the U.S. to capture market share [8][9]. - Future revenue projections for 2025-2027 are 9.416 billion CNY, 10.497 billion CNY, and 11.578 billion CNY, with expected growth rates of 11.45%, 11.47%, and 10.30% respectively [10][12].